Effector Therapeutics Inc (EFTR)vsBeiGene, Ltd. (ONC)
EFTR
Effector Therapeutics Inc
$0.00
0.00%
HEALTHCARE · Cap: $940
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 791460% more annual revenue ($5.34B vs $675,000). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
EFTR
Avoid34
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EFTR.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 117.0% year-over-year
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : EFTR
The strongest argument for EFTR centers on Price/Book, Revenue Growth. Revenue growth of 117.0% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : EFTR
The primary concerns for EFTR are EPS Growth, Market Cap, Profit Margin.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
EFTR carries more volatility with a beta of 0.96 — expect wider price swings.
EFTR is growing revenue faster at 117.0% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (42/100 vs 34/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Effector Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Effector Therapeutics Inc (EFTR) is a clinical-stage biopharmaceutical company pioneering targeted cancer therapies through the selective modulation of RNA translation. By specifically altering protein synthesis within tumor cells, the company is addressing critical unmet needs in oncology with its innovative small molecule treatments. With a robust and diverse pipeline of candidates under development, Effector Therapeutics is dedicated to advancing precision medicine, ultimately striving to improve treatment outcomes and quality of life for cancer patients in an evolving biotechnology landscape.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?